TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexFemale
Age14-65
SponsorBeihua Kong
About this trial
Investigators will conduct the trial to determine whether paclitaxel and cisplatin (PT) has the same curative effects and less adverse effects than bleomycin, etoposide and cisplatin(BEP) among newly diagnosed malignant ovarian germ cell tumor patients after surgery.
Eligibility criteria
Qualifiers
Age≤65 years; female, Chinese women;
Granulosa cell tumor
Granulosa cell-theca cell tumor
Sertoli-Leydig cell tumor (androblastoma)
Disqualifiers
With severe or uncontrolled internal disease, unable to receive surgery and/or unsuitable for chemotherapy;
History of organ transplantation, immune diseases;
History of serious mental illness, a history of brain dysfunction;
Drug abuse or a history of drug abuse;
Trial design
Treatments tested in this trial
- Paclitaxel
- Carboplatin
- Bleomycin
- Etoposide
- Cisplatin
Treatment groups
129 Participants
are divided into 2 treatment groupsSponsors and collaborators
Beihua Kong
Lead sponsor
Shandong University
Sponsor institution
Huazhong University of Science and Technology
Collaborator
Zhejiang University
Collaborator
Sun Yat-sen University
Collaborator
Source ClinicalTrials.gov